<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-157439</identifier>
<setSpec>1699-258X</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Acute pneumonitis in a patient with adult-onset disease after toclizumab treatment with good response to anakinra</dc:title>
<dc:description xml:lang="en">Pulmonary involvement in the form of acute pneumonitis in adult-onset Still's disease (AOSD) is an uncommon manifestation, with few cases reported in the literature. We report the case of a 61-year-old male with 3 years of AOSD evolution, treated with methotrexate (MTX) and half-dose corticosteroids, which debuted with symptoms of fever, dyspnea and dry cough after 3 weeks of receiving the first dose of tocilizumab (TCZ). In the follow-up study showed leukocytosis with left shift, elevated serum ferritin and C-reactive protein standard. The chest CT scan showed ground-glass pattern predominantly in central and upper lobes and the BAL shows an increase in the percentage of lymphocyte with normal subpopulations and negative cultures. MTX and TCM were suspended, prednisone was increased to 30mg/day and within a week Anakinra 100mg/day SC was iniciated, noting in a few days a progressive clinical, analytical and radiological improvement (AU)</dc:description>
<dc:creator>Jara Chinarro, Beatriz</dc:creator>
<dc:creator>Sangüesa Gómez, Clara</dc:creator>
<dc:creator>Espinosa Malpartida, María</dc:creator>
<dc:creator>Barbadillo Mateos, Carmen</dc:creator>
<dc:creator>Flores Robles, Bryan Josué</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La afectación pulmonar en forma de neumonitis aguda en la enfermedad de Still del adulto (ESA) es una manifestación infrecuente, existiendo pocos casos descritos en la literatura. Presentamos el caso de un varón de 61 años con ESA de 3 años de evolución, en tratamiento con metotrexato (MTX) y corticoides a dosis medias, que comenzó con cuadro de fiebre, disnea y tos seca a las 3 semanas de recibir la primera dosis de tocilizumab (TCZ). En la analítica destacaban leucocitosis con desviación izquierda, ferritina sérica muy elevada y proteína C reactiva normal. La TAC de tórax mostró un patrón en vidrio deslustrado de predominio central y lóbulos superiores, y el BAL, un incremento del porcentaje de linfocitos, con subpoblaciones normales y cultivos negativos. Se suspendieron el MTX y el TCZ, se aumentó la prednisona a 30mg/día y al cabo de una semana se inició anakinra 100mg/día por vía subcutánea, observando en pocos días una mejoría progresiva espectacular clínica, analítica y radiológica (AU)</dc:description>
<dc:source>Reumatol. clín. (Barc.);12(6): 345-347, nov.-dic. 2016. ilus</dc:source>
<dc:identifier>ibc-157439</dc:identifier>
<dc:title xml:lang="es">Neumonitis aguda en un paciente con enfermedad de Still del adulto tras tratamiento con tocilizumab con buena respuesta a anakinra</dc:title>
<dc:subject>^d11443^s22016</dc:subject>
<dc:subject>^d4479^s22012</dc:subject>
<dc:subject>^d5402^s22073</dc:subject>
<dc:subject>^d29808^s22080</dc:subject>
<dc:subject>^d29808^s22032</dc:subject>
<dc:subject>^d29808^s29166</dc:subject>
<dc:subject>^d308^s22073</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d29808^s22057</dc:subject>
<dc:subject>^d29808^s22012</dc:subject>
<dc:subject>^d23481^s22045</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d29808^s22016</dc:subject>
<dc:subject>^d8141^s22012</dc:subject>
<dc:subject>^d22622^s22073</dc:subject>
<dc:subject>^d28169^s22073</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d11443^s22012</dc:subject>
<dc:subject>^d32355^s22073</dc:subject>
<dc:type>article</dc:type>
<dc:date>201612</dc:date>
</metadata>
</record>
</ibecs-document>
